Media stories about Marrone Bio Innovations (NASDAQ:MBII) have been trending very positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Marrone Bio Innovations earned a media sentiment score of 0.56 on Accern’s scale. Accern also assigned headlines about the basic materials company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- Contrasting Marrone Bio Innovations (NASDAQ:MBII) and American Vanguard Corporation (AVD) (americanbankingnews.com)
- Marrone Bio Innovations, Inc. (NASDAQ:MBII) Upgraded at ValuEngine (americanbankingnews.com)
- Marrone Bio Innovations, Partner Organizations Celebrate Major Milestone in Testing Invasive Zebra and Quagga Mussel Treatment under Large-Scale Open Water Conditions (finance.yahoo.com)
- Marrone Bio Innovations to Report Second Quarter 2017 Financial Results and Host a Conference Call on Monday, August 14th at 1:30 p.m. Pacific time (finance.yahoo.com)
Several research firms have weighed in on MBII. Zacks Investment Research upgraded Marrone Bio Innovations from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. HC Wainwright reiterated a “buy” rating on shares of Marrone Bio Innovations in a research report on Friday, May 12th. ValuEngine upgraded Marrone Bio Innovations from a “sell” rating to a “hold” rating in a research report on Friday. Piper Jaffray Companies set a $1.00 target price on Marrone Bio Innovations and gave the company a “hold” rating in a research report on Saturday, July 22nd. Finally, Jefferies Group LLC restated a “hold” rating and set a $2.50 price target on shares of Marrone Bio Innovations in a report on Tuesday, May 2nd. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Marrone Bio Innovations presently has a consensus rating of “Hold” and an average target price of $1.75.
Marrone Bio Innovations (MBII) traded down 1.64% during mid-day trading on Tuesday, reaching $1.20. The company’s stock had a trading volume of 21,114 shares. Marrone Bio Innovations has a 12-month low of $0.71 and a 12-month high of $2.79. The stock’s market cap is $37.62 million. The firm’s 50 day moving average price is $1.17 and its 200 day moving average price is $1.63.
ILLEGAL ACTIVITY WARNING: This story was originally reported by BBNS and is owned by of BBNS. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://baseballnewssource.com/markets/marrone-bio-innovations-nasdaqmbii-receives-media-impact-score-of-0-56-updated-updated-updated/1196789.html.
Marrone Bio Innovations Company Profile
Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.
Receive News & Ratings for Marrone Bio Innovations Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations Inc. and related companies with our FREE daily email newsletter.